Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
APGE
Apogee Therapeutics Inc.
$53.48
Strengths
Earnings are forecast to grow
Outperform the market
Upgraded on attractively valued
Chart
$37.52 (+42.54%)
$37.79 (+41.52%)
$37.79 (+41.52%)
$37.79 (+41.52%)
APGE has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
APGE overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Outperform the market
APGE Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
APGE Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
What is APGE current stock price?
What are APGE stock strengths?
What risks are associated with APGE stock?
When is APGE next earnings report?
What is APGE market cap and volume?
What is APGE's current Stock IQ?
Should I buy APGE stock right now?
Is APGE a Strong Buy right now?
What does a 'Strong Buy' rating mean for APGE?
What does a 'Strong Sell' rating mean for APGE?
What factors influence APGE's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
APGE
Apogee Therapeutics Inc.
Current Price
$53.48
Stock Insights
Strengths
Earnings are forecast to grow
Outperform the market
Upgraded on attractively valued
Chart
$37.52 (+42.54%)
$37.79 (+41.52%)
$37.79 (+41.52%)
$37.79 (+41.52%)
APGE Analysts Opinion
APGE Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Outperform the market
APGE Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
APGE Street view is extremely bullish and have positive views on the near-term outlook
APGE has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Average key support and resistance price levels.
APGE Latest Analysis
Mizuho Initiates Coverage of Apogee Therapeutics (APGE) with Outperform Recommendation. Fintel reports that on October 21 2025 Mizuho initiated coverage of Apogee Therapeutics (NasdaqGM:APGE) with a Outperform recommendation. Analyst Price Forecast Suggests 71.00% Upside
Today
Does Apogee Therapeutics Inc. (APGE) Have the Potential to Rally 72.52% as Wall Street Analysts Expect?. The consensus price target hints at a 72.5% upside potential for Apogee Therapeutics Inc. (APGE). While empirical research shows that this sought-after metric is hardly effective an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Tue Oct 14, 2025
Apogee Therapeutics Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares for Gross Proceeds of $345 Million. ) a clinical-stage biotechnology company advancing optimized novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&.I) markets today announced the closing of its previously announced underwritten public offering of 8048782 shares of its common stock including the full exerc
Fri Oct 10, 2025
Apogee Therapeutics Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares for Gross Proceeds of $345 Million.
Fri Oct 10, 2025
Apogee Therapeutics prices $300M public offering.
Thu Oct 9, 2025
Apogee Therapeutics announces underwritten public offering.
Wed Oct 8, 2025
Apogee Therapeutics stock falls after announcing proposed public offering.
Wed Oct 8, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
APGE Stock trends
APGE Stock performance
APGE Stock analysis
APGE investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.